We audit the AI Narrative for Top 100 Life Science Portfolios. We document instances where LLMs prioritize unapproved drugs, hallucinate device safety data, and bypass FDA-approved clinical evidence.
Includes the Cross-Category Mechanism Analysis
Three critical vulnerabilities where AI models may be misrepresenting your products to patients and healthcare providers
Is Copilot positioning "Investigational Phase 3" compounds as superior to your approved First-Line Therapy?
Is ChatGPT confusing your current-gen device with a competitor's recalled product data?
Are LLMs misinterpreting "Sensitivity vs. Specificity" data, leading to false-negative patient advice?
You invest millions in clinical trials and regulatory approval (NDA/PMA). But Generative AI models do not "read" clinical papers like doctors do. They scan for Structured Data Patterns.
Because LLMs prioritize structured data, AI models have been observed recommending competitors or unapproved compounds—even if your clinical evidence is superior.
AI models generating patient advice that contradicts your specific Indications for Use (IFU) or Safety Labeling.
High-intent patient queries being answered with competitor data, unapproved drugs, or obsolete protocols.
Trusted clinical data being buried under "AI Summaries" that cite outdated or unverified sources.
Understand exactly how AI models position your clinical assets today